About Aveo Oncology
Aveo Oncology is a Healthcare company based in Cambridge (United States) founded in 2001, and was acquired by LG Chem in October 2022. Small molecule drugs for cancer treatment are developed. It operates on a HealthTech model. Aveo Oncology has raised $266.4 million across 11 funding rounds from investors including Bessemer Venture Partners, LG Chem and Biogen. The company has 114 employees. Aveo Oncology offers products and services including FOTIVDA, Ficlatuzumab, and AV-380. Its focus areas include Biotechnology and Oncology. Its legal entity is AVEO Pharmaceuticals, Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Aveo Oncology, a subsidiary of LG Chem, is dedicated to the development of innovative medicines for cancer patients. The company is engaged in the biotechnology sector with a primary focus on oncology. Solutions such as FOTIVDA, Ficlatuzumab, and AV-380 are being researched and developed to improve patient outcomes. The organization is headquartered in Boston, Massachusetts, and is committed to advancing scientific research and partnerships in the field of cancer treatment.
- Headquarters Cambridge, United States
- Employees 114
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website aveooncology.com
- Social LinkedIn X Facebook
- Acquired by LG Chem (Oct 2022)
- Legal Name Aveo Pharmaceuticals, Inc.
- Annual Revenue$42.3 M (USD)603as on Dec 31, 2021
- Total Equity Funding$266.4M (USD)
in 11 rounds
- InvestorsBessemer Venture Partners
& 16 more
- Employee Count114
- Acquired byLG Chem
(Oct 2022)
Products & Services of Aveo Oncology
Aveo Oncology offers a comprehensive portfolio of products and services, including FOTIVDA, Ficlatuzumab, and AV-380.
FOTIVDA is developed for treating cancer patients effectively.
Ficlatuzumab is researched for potential cancer treatment solutions.
AV-380 is explored for innovative cancer therapy options.
Funding Insights of Aveo Oncology
Aveo Oncology has successfully raised a total of $266.4M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $266.4M
- Total Rounds 11
- First Round $42.7M
(Oct 2003)
- Investors Count 16
Latest 10 of 11 funding rounds of Aveo Oncology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | Post-IPO | – | – | ||
| May 2011 | $7.5M | Post-IPO | – | – | – |
| Nov 2010 | $60.8M | Post-IPO | – | – | – |
| Jun 2010 | $25M | Post-IPO | – | – | |
| May 2010 | $25M | Series F | – | – | |
| Jul 2009 | $20M | Series E | – | – | – |
| Mar 2009 | $30M | Series D | – | – | – |
| May 2007 | $53M | Series D | – | – | |
| May 2007 | $53M | Series D | – | – | |
| Oct 2003 | $42.7M | Series B | – | – |
17 investors in total: 17 institutional.
Investors in Aveo Oncology
Aveo Oncology has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Bessemer Venture Partners, LG Chem and Biogen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Venture capital investments and support for entrepreneurs in technology and innovation sectors. | 1911 | bvp.com | Redwood City, United States | |
| vaterahealthcare.com | ||||
Venture capital investment and entrepreneur support services. | hcp.com | |||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Investments are made in US life sciences and healthtech firms. | prospectventures.com | Palo Alto, United States | ||
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Early stage VC firm investing in the US and Korea | oxbio.com | Boston, United States | ||
Venture capital firm specializing in early-stage tech investments and founder support. | 1965 | greylock.com |
Investor details for Aveo Oncology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aveo Oncology
63 people are tracked at Aveo Oncology (39 in leadership, 24 in team); the tracked headcount is 114.
| Name | Role | Group |
|---|---|---|
Chris Wixson | Senior Director, Distribution & Gpos | Leadership |
Jason Noto | Vice President, Market Access | Leadership |
David Crist | VP, Sales | Leadership |
Mike Ferraresso | Chief Commercial Officer | Leadership |
Jason M. Noto | Senior Vice President, US Market Access & Alliance Management | Leadership |
Stacy Luhman | Director, Sales Operations | Leadership |
Anisha Wharton | Head of Regulatory Affairs | Leadership |
Frank Ferrara | Senior Director, Medical Writing | Leadership |
Penny Butler | Senior Director Patient Support Services | Leadership |
Dorota Brousmiche | Director, GXP Quality Assurance | Leadership |
Kim Coppom | Executive Director, National Accounts And Federal Markets | Leadership |
Michael P. Bailey | President & CEO | Leadership |
Stephen Wilkinson | Director, National Accounts | Leadership |
Angela Shakespeare | Sr. Director, Thought Leader Engagement & Strategic Partnerships | Leadership |
Lance Rogers Mba, Pmp | Director Of Strategy, Planning And Operations | Leadership |
Michael McDole | Executive Director, Head Of Trade & Distribution | Leadership |
Dilip K. | Senior Director, Regulatory CMC | Leadership |
Reetu Dandora | Senior Vice President, Quality And Regulatory Compliance | Leadership |
Caryn Cox | Regional Business Director | Leadership |
Samuel J. Villa | Senior Director, Federal Markets | Leadership |
43 more people are available in the full profile.
Complete people profiles for Aveo Oncology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aveo Oncology
5 dated milestones of Aveo Oncology across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Aveo Oncology is founded.
- Funding First funding round of $42.7M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
- Exit Acquired by LG Chem.
Competitors of Aveo Oncology
Aveo Oncology has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Aveo Oncology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aveo Oncology
The website of Aveo Oncology (aveooncology.com) receives about 5.3K visits a month and ranks #4,236,239 among all websites worldwide, #5,229 in Biotechnology and Pharmaceuticals.
- Monthly visits5.3K
▲ 26.6% vs previous month
- Unique visitors1.8K
per month
- Global rank#4,236,239
among all websites
- Category rank#5,229
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit1.8
- Average visit36 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with Aveo Oncology. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| arqule.com | 100% | View details | |||
| ariad.com | 84% | View details | |||
merrimackpharma.com | merrimackpharma.com | 77% | – | ||
| acceleronpharma.com | 75% | View details | |||
| biodesix.com | 73% | 7.4K | #2,413,737 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Aveo Oncology
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Aveo Oncology (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aveo Oncology
Complete news archive for Aveo Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aveo Oncology
Aveo Oncology was founded in 2001 and raised its 1st funding round 2 years after it was founded.
Aveo Oncology is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Aveo Oncology is a funded company, having raised a total of $266.4M across 11 funding rounds to date. The company's 1st funding round was a Series B of $42.7M, raised on Oct 2003.
Aveo Oncology has 114 employees.
Annual revenue of Aveo Oncology is $42.3M as on Dec 31, 2021.
Aveo Oncology, a subsidiary of LG Chem, is dedicated to the development of innovative medicines for cancer patients. The company is engaged in the biotechnology sector with a primary focus on oncology. Solutions such as FOTIVDA, Ficlatuzumab, and AV-380 are being researched and developed to improve patient outcomes. The organization is headquartered in Boston, Massachusetts, and is committed to advancing scientific research and partnerships in the field of cancer treatment.
Aveo Oncology offers FOTIVDA, Ficlatuzumab, and AV-380.
Aveo Oncology has 17 investors. Key investors include Bessemer Venture Partners, LG Chem, Biogen, Hercules Capital, and Flagship Pioneering.
Aveo Oncology operates through Aveo Pharmaceuticals, Inc..
Yes. Aveo Oncology was acquired by LG Chem in October 2022.